Open Access

Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

  • Denise A. Yardley1Email author,
  • Adam Brufsky2,
  • Robert E. Coleman3,
  • Pierfranco F. Conte4,
  • Javier Cortes5,
  • Stefan Glück6,
  • Jean-Mark A. Nabholtz7,
  • Joyce O’Shaughnessy8,
  • Robert M. Beck6,
  • Amy Ko6,
  • Markus F. Renschler6,
  • Debora Barton6 and
  • Nadia Harbeck9
Trials201617:63

https://doi.org/10.1186/s13063-016-1195-6

Published: 3 February 2016

The original article was published in Trials 2015 16:575

Unfortunately, the original version of this article [1] contained a few formatting errors which have been corrected via an update. In the eighth paragraph of the background there was an error. The original read as, “A phase II study evaluating the combination of nab-paclitaxel plus carboplatin as 199 first-line treatment for mTNBC is currently under way [31].” But should have read as “A phase II study evaluated the combination of nab-paclitaxel plus carboplatin a first-line treatment for mTNBC [31].”

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Sarah Cannon Research Institute and the Tennessee Oncology, PLLC
(2)
University of Pittsburgh Medical Center
(3)
Weston Park Hospital, Sheffield Cancer Research Center
(4)
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, and Istituto Oncologico Veneto IRCCS
(5)
Vall d’Hebron Institute of Oncology (VHIO)
(6)
Celgene Corporation
(7)
Centre de Lutte Contre le Cancer d’Auvergne
(8)
Texas Oncology-Baylor Charles A. Sammons Center; US Oncology
(9)
Breast Center, University of Munich

Reference

  1. Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, et al. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials. 2015;16:575.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Yardley et al. 2016

Advertisement